These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 12727949)

  • 1. Increase of estrogen dose deteriorates mood during progestin phase in sequential hormonal therapy.
    Björn I; Sundström-Poromaa I; Bixo M; Nyberg S; Bäckström G; Bäckström T
    J Clin Endocrinol Metab; 2003 May; 88(5):2026-30. PubMed ID: 12727949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse mood effects during postmenopausal hormone treatment in relation to personality traits.
    Björn I; Bäckström T; Lalos A; Sundström-Poromaa I
    Climacteric; 2006 Aug; 9(4):290-7. PubMed ID: 16857659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of different doses of medroxyprogesterone acetate on mood symptoms in sequential hormonal therapy.
    Björn I; Bixo M; Nöjd KS; Collberg P; Nyberg S; Sundström-Poromaa I; Bäckström T
    Gynecol Endocrinol; 2002 Feb; 16(1):1-8. PubMed ID: 11915576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Negative mood changes during hormone replacement therapy: a comparison between two progestogens.
    Björn I; Bixo M; Nöjd KS; Nyberg S; Bäckström T
    Am J Obstet Gynecol; 2000 Dec; 183(6):1419-26. PubMed ID: 11120505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity to a neurosteroid is increased during addition of progestagen to postmenopausal hormone replacement therapy.
    Wihlbäck AC; Sundström-Poromaa I; Nyberg S; Bäckström T
    Neuroendocrinology; 2001 Jun; 73(6):397-407. PubMed ID: 11408781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between allopregnanolone and negative mood in postmenopausal women taking sequential hormone replacement therapy with vaginal progesterone.
    Andréen L; Sundström-Poromaa I; Bixo M; Andersson A; Nyberg S; Bäckström T
    Psychoneuroendocrinology; 2005 Feb; 30(2):212-24. PubMed ID: 15471618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
    Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
    Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estradiol and the addition of progesterone increase the sensitivity to a neurosteroid in postmenopausal women.
    Wihlbäck AC; Nyberg S; Bäckström T; Bixo M; Sundström-Poromaa I
    Psychoneuroendocrinology; 2005 Jan; 30(1):38-50. PubMed ID: 15358441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled, cross-over trial to assess the side effects of medroxyprogesterone acetate in hormone replacement therapy.
    Kirkham C; Hahn PM; Van Vugt DA; Carmichael JA; Reid RL
    Obstet Gynecol; 1991 Jul; 78(1):93-7. PubMed ID: 1828550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal bone loss: a comparison of high- and low-dose estrogen-progestin regimens.
    Heikkinen J; Vaheri R; Kainulainen P; Timonen U
    Osteoporos Int; 2000; 11(11):929-37. PubMed ID: 11193245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder.
    Segebladh B; Borgström A; Nyberg S; Bixo M; Sundström-Poromaa I
    Am J Obstet Gynecol; 2009 Aug; 201(2):139.e1-8. PubMed ID: 19398092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of estrogen plus progestin on menopausal symptoms in women with systemic lupus erythematosus: a randomized, double-blind, controlled trial.
    Cravioto MD; Durand-Carbajal M; Jiménez-Santana L; Lara-Reyes P; Seuc AH; Sánchez-Guerrero J
    Arthritis Care Res (Hoboken); 2011 Dec; 63(12):1654-63. PubMed ID: 22127965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous combined hormone replacement therapy relieves climacteric symptoms and improves health-related quality of life in early postmenopausal women.
    Pitkin J; Smetnik VP; Vadász P; Mustonen M; Salminen K; Ylikangas S;
    Menopause Int; 2007 Sep; 13(3):116-23. PubMed ID: 17785037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
    Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
    Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women.
    Mattsson LA; Skouby S; Rees M; Heikkinen J; Kudela M; Stadnicki-Kolendo A; Mattila L; Salminen K; Vuorela A; Mustonen M;
    Menopause Int; 2007 Sep; 13(3):124-31. PubMed ID: 17785038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allopregnanolone concentration and mood--a bimodal association in postmenopausal women treated with oral progesterone.
    Andréen L; Sundström-Poromaa I; Bixo M; Nyberg S; Bäckström T
    Psychopharmacology (Berl); 2006 Aug; 187(2):209-21. PubMed ID: 16724185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind, placebo-controlled psychometric studies on the effects of a combined estrogen-progestin regimen versus estrogen alone on performance, mood and personality of menopausal syndrome patients.
    Linzmayer L; Semlitsch HV; Saletu B; Böck G; Saletu-Zyhlarz G; Zoghlami A; Gruber D; Metka M; Huber J; Oettel M; Gräser T; Grünberger J
    Arzneimittelforschung; 2001; 51(3):238-45. PubMed ID: 11304940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
    Rozenberg S; Ylikorkala O; Arrenbrecht S
    Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cyclical gestagen (MPA) supplement for continuous transdermal or oral estrogen substitution in postmenopause: modification of serum lipids].
    Hänggi W; Birkhäuser MH; Malek A; Peheim E; von Hospenthal JU
    Geburtshilfe Frauenheilkd; 1993 Oct; 53(10):709-14. PubMed ID: 8270155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of hormone-replacement therapy on endogenous nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate.
    Imthurn B; Rosselli M; Jaeger AW; Keller PJ; Dubey RK
    J Clin Endocrinol Metab; 1997 Feb; 82(2):388-94. PubMed ID: 9024224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.